Jump to section
Ginkgo Bioworks' mission is to make biology easy to engineer.
28% employee growth in 12 months
Research into the programmable nature of biological cells presents massive opportunities for almost every industry, but the technology is hardly accessible. Bespoke programming of cells requires cutting-edge lab equipment and an in-depth understanding of microbiology, something that would not seem feasible to the average product designer.
Ginkgo Bioworks sells programmable cell development services to provide access to the technology to industries outside of medicine. Whilst the company has already worked on medical products such as vaccines for Moderna, it will research and design products based on programmed cells for any product that it believes holds value.
The startup’s approach to providing cell programming services outside of the medical sector is smart, as an increasingly high number of industries recognize the potential for bespoke cell-based materials. Ginkgo also provides an opportunity for innovation where it previously was not possible by taking the research and design into its own hands where companies would usually need to facilitate such services within their company.
Kirsty
Company Specialist at Welcome to the Jungle
May 2020
$70m
LATE VC
Sep 2019
$290m
SERIES E
This company has top investors
Reshma Shetty
(COO)Reshma studied for a PhD in Biological Engineering at MIT, having worked as a Research Assistant at Cambridge and Utah universities. They co-founded Ginkgo Bioworks in September 2008.
Barry Canton
(CTO)Barry studied at University College Dublin before taking a PhD in Biological Engineering at MIT. They co-founded Ginkgo Bioworks in 2008 on graduation, working there since.
Jason Kelly
(CEO)Previously founded OpenWetWare while a graduate student at MIT. At MIT they earned a PhD in Biological Engineering.